Dr. Reddys Laboratories Ltd.

Dr. Reddy's is currently trading at Rs. 3859.75, up by 24.45 points or 0.64% from its previous closing of Rs. 3835.30 on the BSE.

The scrip opened at Rs. 3841.00 and has touched a high and low of Rs. 3879.00 and Rs. 3806.45 respectively. So far 13607 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4095.00 on 22-Apr-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4091.55 and Rs. 3805.95 respectively. The current market cap of the company is Rs. 64009.49 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.

Dr. Reddy's Laboratories and its subsidiaries have launched Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection, 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).

The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9 million MAT for the most recent twelve months ending in March 2020. Dr. Reddy’s Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single dose ampules.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.